• Member Login
• Sitemap
• Contact
• RSS feed

Galapagos increases share capital through warrant exercises

06/04/2012

Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises.

Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period from 16 March through 29 March 2012, Galapagos issued 137,414 new ordinary shares on 5 April 2012 for a total capital increase (including issuance premium) of €1,099,662.27. No member of the Board or Executive Committee exercised warrants.

To date, Galapagos' total share capital amounts to €143,669,252.55; the total number of securities conferring voting rights is 26,558,855, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities which confer voting rights is 3,190,376 which is also the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 50 discovery programs. The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com

Source: Galapagos